Vericel Corp (NASDAQ:VCEL)

3.57
Delayed Data
As of Jun 30
 +0.05 / +1.42%
Today’s Change
2.55
Today|||52-Week Range
4.35
+17.43%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Medical Specialties
MARKET CAP
$83.7M

Company Description

Vericel Corp. engages in the development of patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company markets two cell therapy products in the United States, Carticel (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee and Epicel (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area.Vericel was founded on March 24, 1989 and is headquartered in Cambridge, MA.

Contact Information

Vericel Corp.
64 Sidney Street
Cambridge Massachusetts 02139
P:(617) 588-5555
Investor Relations:

Employees

Shareholders

Other institutional51.78%
Mutual fund holders4.31%
Individual stakeholders0.22%

Top Executives

Dominick C. ColangeloPresident & Chief Executive Officer
Daniel R. OrlandoChief Operating Officer
Gerard J. MichelChief Financial Officer & VP-Corporate Development
David ReckerChief Medical Officer
Ross TuboChief Scientific Officer

To view my watchlist

Not a member yet?

Sign up now for a free account